Experiments feeding these yeasts to honeybees shows that the presence of these sterols can improve their reproduction,” says APIX Biosciences’ Chairman Thierry Bogaert. “This confirms and extends the ...

The securities described above are being offered by Invivyd pursuant to a shelf registration statement on Form S-3 (File No. 333-267643) filed with the U.S. Securities and Exchange Commission (SEC) on ...

An adjusted EBITDA margin expected at around 39% by 2030, based on current currency exchange rates. The strategy period includes synergies, as well as significant investments in innovation, commercial ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist, previously approved as IMCIVREE ® by the FDA, the EMA, and UK’s Medicines & Healthcare Products Regulatory Agency (MHRA) for obesity due to ...

Jason Wild, Executive Chairman of TerrAscend, stated, “We believe our shares represent compelling value at current levels, especially in the context of recent federal regulatory momentum. This program ...

INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

For nearly five decades, Glaucoma Research Foundation has harnessed donor support to advance its mission to cure glaucoma—the leading cause of irreversible blindness. With no cure and everyone at risk ...

NANTES, France, August 20, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the appointment of Thomas Gidoin as Chief Financial Officer. Thomas joins the ...

I am thrilled to welcome Ramón to the leadership team at Aligos,” said Sushmita Chanda, PhD, DABT, Executive Vice President, Chief Development Officer at Aligos. “As we progress ALG-000184 through the ...

OneMedNet Corporation (Nasdaq:ONMD) (“OneMedNet” or the “Company”), a leader in AI-powered Real-World Data (RWD), announced the addition of 85 cardiovascular centers and data sources, expanding its ...

U.S. Senate Appropriations Report Further Validates Adial’s Therapeutic Approach and Promotes a More Contemporary Patient Focused Regulatory Environment GLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) ...

This study shows that a pre-treatment with blarcamesine prevented Amyloid beta-induced memory impairment and brain oxidative injury suggesting that blarcamesine is an attractive candidate for ...